CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody by Cristina Melero, S. Jimmy Budiardjo, Anahita Daruwalla, Lance Larrabee, Oleg Ganichkin, Alexander J. Heiler, Jill Fenaux, Ben Chung, Germaine Fuh, Yao-Ming Huang

“…Human CD200R1 (hCD200R1), an immune inhibitory receptor expressed predominantly on T cells and myeloid cells, was identified as a promising immuno-oncology target by the 23andMe database. Blockade of CD200R1-dependent signaling enhances T cell-mediated antitumor activity in vitro and in vivo. 23ME–00610 is a potential first-in-class, humanized IgG1 investigational antibody that binds hCD200R1 with high affinity. …”
Get full text

Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing by Seon-Hee Yim, Yeun-Jun Chung

“…In November 2013, the US Food and Drug Administration (FDA) sent a warning letter to 23andMe, Inc. and ordered the company to discontinue marketing of the 23andMe Personal Genome Service (PGS) until it receives FDA marketing authorization for the device. …”
Get full text

High Energy X-Ray Detection by MicroPattern Gaseous Detector by Saeedeh Khezripour, Mohammad Reza Rezai Rayeni

“… Purpose: The paper aims to discuss the response of the Micro-Mesh Gaseous Structure (Micromegas) detector to high-energy X-ray with 2.3 MeV energy using photon to neutron converters in addition to optimization of the detector components by Monte Carlo simulation. …”
Get full text